Effects of calcimimetic combined with an angiotensin-converting enzyme inhibitor on uremic cardiomyopathy progression

American Journal of Nephrology

Volumn 34, Issue 3, 2011, Pages 256-267

  Mizobuchi, Masahide ^a   Ogata, Hiroaki ^b   Hosaka, Nozomu ^a   Kumata, Chiaki ^a   Nakazawa, Ai ^a   Kondo, Fumiko ^a   Koiwa, Fumihiko ^c   Kinugasa, Eriko ^b   Akizawa, Tadao ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^c SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Calcimimetics; Cardiovascular disease; Uremic cardiomyopathy

Indexed keywords

CYCLIN D1; CYCLIN D2; CYCLINE; ENALAPRIL; FIBRONECTIN; TECALCET; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CARDIOMYOPATHY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; HEART VENTRICLE HYPERTROPHY; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; UREMIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANILINE COMPOUNDS; ANIMALS; CALCIUM; CARDIOMYOPATHIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENALAPRIL; MALE; RATS; RATS, SPRAGUE-DAWLEY; UREMIA;

EID: 79960677612     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000330188     Document Type: Article

References (44)

1. Gross ML, Ritz E: Hypertrophy and fibrosis in the cardiomyopathy of uremia - beyond coronary heart disease. Semin Dial 2008;21:308-318.
2. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995;5:2024-2031.
3. Johnstone LM, Jones CL, Grigg LE, Wilkinson JL, Walker RG, Powell HR: Left ventricular abnormalities in children, adolescents and young adults with renal disease. Kidney Int 1996;50:998-1006. (Pubitemid 26302690)
4. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-354. (Pubitemid 26075843)
5. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-290. (Pubitemid 19202488)
6. Rasic S, Kulenovic I, Haracic A, Catovic A: Left ventricular hypertrophy and risk factors for its development in uraemic patients. Bosn J Basic Med Sci 2004;4:34-40.
7. Blacher J, Demuth K, Guerin AP, Vadez C, Moatti N, Safar ME, London GM: Association between plasma homocysteine concentrations and cardiac hypertrophy in endstage renal disease. J Nephrol 1999;12:248-255. (Pubitemid 29425998)
8. Demuth K, Blacher J, Guerin AP, Benoit MO, Moatti N, Safar ME, London GM: Endothelin and cardiovascular remodelling in endstage renal disease. Nephrol Dial Transplant 1998;13:375-383. (Pubitemid 28062199)
9. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001;12:1508-1515. (Pubitemid 32666334)
10. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kid ney Int 2002;62:339-345. (Pubitemid 34754080)
11. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS: Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2002;40:68-75. (Pubitemid 34701213)
12. Schluter KD, Piper HM: Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 1998;37:34-41. (Pubitemid 28122613)
13. Drueke T, Fauchet M, Fleury J, Lesourd P, Toure Y, Le Pailleur C, de Vernejoul P, Crosnier J: Effect of parathyroidectomy on leftventricular function in haemodialysis patients. Lancet 1980;1:112-114. (Pubitemid 10193044)
14. Nagashima M, Hashimoto K, Shinsato T, Ashida K, Kobayashi M, Yamashita H, Otsuka M, Naruko T, Itoh A, Haze K: Marked improvement of left ventricular function after parathyroidectomy in a hemodialysis patient with secondary hyperparathyroidism and left ventricular dysfunction. Circ J 2003;67:269-272. (Pubitemid 36362506)
15. Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S: Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol 1997;8:1764-1770. (Pubitemid 27475878)
16. Ellmers LJ, Scott NJ, Medicherla S, Pilbrow AP, Bridgman PG, Yandle TG, Richards AM, Protter AA, Cameron VA: Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction. Endocrinology 2008;149:5828-5834.
17. Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC: Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 2002;15:157-163. (Pubitemid 34161091)
18. Rosenkranz S: TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004;63:423-432. (Pubitemid 38970186)
19. de Cavanagh E M, Ferder M, Inserra F, Ferder L: Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Physiol Heart Circ Physiol 2009;296:H550-H558.
20. Domenighetti AA, Wang Q, Egger M, Richards SM, Pedrazzini T, Delbridge LM: Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension 2005;46:426-432. (Pubitemid 41099180)
21. Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R: Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008;52:501-506.
22. Matsumoto Y, Sato M, Ohashi H, Araki H, Tadokoro M, Osumi Y, Ito H, Morita H, Amano I: Effects of L-carnitine supplementation on cardiac morbidity in hemodialyzed patients. Am J Nephrol 2000;20:201-207. (Pubitemid 30445314)
23. Drueke TB, Ritz E: Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol 2009;4:234-241.
24. Evenepoel P: Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney Int 2008;74:265-275. (Pubitemid 352001237)
25. Kawata T, Nagano N, Obi M, Miyata S, Koyama C, Kobayashi N, Wakita S, Wada M: Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 2008;74:1270-1277.
26. Rodriguez M, Aguilera-Tejero E, Mendoza FJ, Guerrero F, Lopez I: Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease. Kidney Int Suppl 2008:S50-S54.
27. Koleganova N, Piecha G, Ritz E, Bekeredjian R, Schirmacher P, Schmitt CP, Gross ML: Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic. Lab Invest 2009;89:520-530.
28. Ogata H, Ritz E, Odoni G, Amann K, Orth SR: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003;14:959-967. (Pubitemid 36359277)
29. Wang LN, Wang C, Lin Y, Xi YH, Zhang WH, Zhao YJ, Li HZ, Tian Y, Lv YJ, Yang BF, Xu CQ: Involvement of calcium-sensing receptor in cardiac hypertrophy-induced by angiotensin II through calcineurin pathway in cultured neonatal rat cardiomyocytes. Biochem Biophys Res Commun 2008;369:584-589.
30. Wang R, Xu C, Zhao W, Zhang J, Cao K, Yang B, Wu L: Calcium and polyamine regulated calcium-sensing receptors in cardiac tissues. Eur J Biochem 2003;270:2680-2688. (Pubitemid 36733535)
31. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E: Combination therapy with an angiotensinconverting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796-1806. (Pubitemid 46870316)
32. Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E: Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol 2009;29:465-472.
33. Ghosh SS, Salloum FN, Abbate A, Krieg R, Sica DA, Gehr TW, Kukreja RC: Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats. Am J Physiol Heart Circ Physiol 2010;299:H975-H984.
34. Suzuki H, Schaefer L, Ling H, Schaefer RM, Dammrich J, Teschner M, Heidland A: Prevention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases. Am J Nephrol 1995;15:129-136.
35. Tfelt-Hansen J, Hansen J L, Smajilovic S, Terwilliger EF, Haunso S, Sheikh SP: Calcium receptor is functionally expressed in ratneonatal ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol 2006;290:H1165-H1171.
36. Brooks G, Poolman RA, Li JM: Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors. Cardiovasc Res 1998;39:301-311. (Pubitemid 28346526)
37. Busk PK, Bartkova J, Strom CC, Wulf-Andersen L, Hinrichsen R, Christoffersen TE, Latella L, Bartek J, Haunso S, Sheikh SP: Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro. Cardiovasc Res 2002;56:64-75. (Pubitemid 35247803)
38. Guo J, Gertsberg Z, Ozgen N, Steinberg SF: P66Shc links alpha1-adrenergic receptors to a reactive oxygen species-dependent AKT-FOXO3A phosphorylation pathway in cardiomyocytes. Circ Res 2009;104:660-669.
39. Drueke TB: Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000;11:1141-1152. (Pubitemid 30367946)
40. Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, Sakaguchi T, Negi S, Kinugasa E, Koshikawa S, Akizawa T: Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004;15:2579-2587. (Pubitemid 41103364)
41. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997;100:2977-2983. (Pubitemid 28022834)
42. Koleganova N, Piecha G, Ritz E, Schmitt CP, Gross ML: A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 2009;75:60-71.
43. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P, Guttmann RD: Left ventricular hypertrophy in end-stage renal disease. Nephron 1988;48:107-115.
44. Amann K, Ritz E, Wiest G, Klaus G, Mall G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994;4:1814-1819.